[go: up one dir, main page]

NO20013731L - Diazabicykliske derivater som nikotinacetylkolinreseptorligander - Google Patents

Diazabicykliske derivater som nikotinacetylkolinreseptorligander

Info

Publication number
NO20013731L
NO20013731L NO20013731A NO20013731A NO20013731L NO 20013731 L NO20013731 L NO 20013731L NO 20013731 A NO20013731 A NO 20013731A NO 20013731 A NO20013731 A NO 20013731A NO 20013731 L NO20013731 L NO 20013731L
Authority
NO
Norway
Prior art keywords
group
covalent bond
acetylcholine receptor
receptor ligands
nicotinic acetylcholine
Prior art date
Application number
NO20013731A
Other languages
English (en)
Other versions
NO20013731D0 (no
Inventor
William H Bunnelle
Daniela Barlocco Cristina
Jerome F Daanen
Michael J Dart
Michael D Meyer
Keith B Ryther
Michael R Schrimpf
Kevin B Sippy
Richard B Toupence
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20013731D0 publication Critical patent/NO20013731D0/no
Publication of NO20013731L publication Critical patent/NO20013731L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

orbindelser med formel I eller et farmasøytisk akseptabelt salt derav, hvori: V velges fra gruppen bestående av en kovalent binding og CH; W velges fra gruppen bestående av en kovalent binding, CHog CHCH; X velges fra gruppen bestående av en kovalent binding og CH, Y velges fra gruppen bestående av en kovalent binding, CHog CHCH, Z velges fra gruppen bestående av CHog CHCH, og CHCHCH; L velges fra gruppen bestående av en kovalent binding og (CH); n er 1-5; Rj velges fra gruppen bestående av (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), og (1);velges fra gruppen bestående av hydrogen, alkoksykarbo-nyl, alkyl, aminoalkyl, aminokarbonylalkyl, benzyloksykar-bonyl, cyanoalkyl, dihydro-3-pyridinylkarbonyl, hydroksy, hydroksyalkyl, fenoksykarbonyl, og -NH; er anvendbare for å kontrollere synaptisk transmisjon i pattedyr.
NO20013731A 1999-01-29 2001-07-30 Diazabicykliske derivater som nikotinacetylkolinreseptorligander NO20013731L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23983899A 1999-01-29 1999-01-29
PCT/US2000/001620 WO2000044755A1 (en) 1999-01-29 2000-01-25 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands

Publications (2)

Publication Number Publication Date
NO20013731D0 NO20013731D0 (no) 2001-07-30
NO20013731L true NO20013731L (no) 2001-09-18

Family

ID=22903947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013731A NO20013731L (no) 1999-01-29 2001-07-30 Diazabicykliske derivater som nikotinacetylkolinreseptorligander

Country Status (26)

Country Link
EP (2) EP1147112B1 (no)
JP (1) JP4676062B2 (no)
KR (1) KR20010101725A (no)
CN (2) CN1636996A (no)
AR (1) AR034538A1 (no)
AT (2) ATE394401T1 (no)
AU (1) AU773795B2 (no)
BG (1) BG105836A (no)
BR (1) BR0007664A (no)
CA (1) CA2361525C (no)
CO (1) CO5150231A1 (no)
CZ (1) CZ20012716A3 (no)
DE (2) DE60006213T2 (no)
DK (1) DK1147112T3 (no)
ES (2) ES2305373T3 (no)
HK (1) HK1043116B (no)
HU (1) HUP0200332A3 (no)
IL (1) IL144340A0 (no)
NO (1) NO20013731L (no)
NZ (1) NZ512884A (no)
PT (1) PT1147112E (no)
SK (1) SK10692001A3 (no)
TR (1) TR200102162T2 (no)
TW (1) TW200300021A (no)
WO (1) WO2000044755A1 (no)
ZA (1) ZA200105835B (no)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
KR100408138B1 (ko) 1997-12-31 2003-12-01 화이자 프로덕츠 인코포레이티드 아릴 융합된 아자폴리사이클릭 화합물
EP1274710B1 (en) * 1999-12-14 2005-02-23 NeuroSearch A/S Novel heteroaryl-diazabicycloalkanes
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6440970B1 (en) 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
US6852721B2 (en) 2000-05-25 2005-02-08 Targacept, Inc. Pharmaceutical compositions and methods for use
CN1185233C (zh) * 2000-07-04 2005-01-19 神经研究公司 芳基和杂芳基-二氮杂双环烷烃,其制备和用途
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2438815A1 (en) * 2001-03-02 2002-09-12 Neurosearch A/S Novel 2,5-diazabicyclo[2.2.1]heptane derivatives
US20040147505A1 (en) * 2001-06-01 2004-07-29 Dan Peters Novel heteroaryl-diazabicyclo alkanes as cns-modulators
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
WO2003094831A2 (en) * 2002-05-07 2003-11-20 Neurosearch A/S Novel diazabicyclic biaryl derivatives
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
KR20060036105A (ko) 2003-07-29 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
TWI345974B (en) 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
SG150534A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
US7396833B2 (en) * 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ATE450263T1 (de) 2004-02-04 2009-12-15 Neurosearch As Diazabicyclische aryl-derivate als cholinerge rezeptor-modulatoren
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
ITMI20040954A1 (it) * 2004-05-12 2004-08-12 Univ Degli Studi Milano Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
SG154432A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
CA2569826C (en) 2004-06-30 2013-07-16 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
ATE495178T1 (de) 2005-02-16 2011-01-15 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin- acetylcholin-rezeptoren
EP1866314B1 (en) 2005-02-16 2010-09-15 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1963323B1 (en) 2005-12-06 2010-07-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
CN101448828B (zh) * 2006-02-10 2011-12-07 神经研究公司 作为烟碱性乙酰胆碱受体激动剂的3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物
US7700596B2 (en) 2006-02-10 2010-04-20 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2007213670A1 (en) * 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1987031A1 (en) 2006-02-10 2008-11-05 NeuroSearch A/S 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
EP1987033B1 (en) * 2006-02-14 2010-08-25 NeuroSearch A/S Diazabicycloalkane derivatives and their medical use
JP2009526777A (ja) 2006-02-14 2009-07-23 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体作用薬としての3,9−ジアザビシクロ(3.3.1)ノナ−3−イル−アリールメタノン誘導体
EP2018380B1 (en) * 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009537599A (ja) 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ 新規8,10−ジアザ−ビシクロ[4.3.1]デカン誘導体及びそれらの医学的使用
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
EP1977746B8 (en) 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
AU2008255005B2 (en) * 2007-05-18 2013-05-02 Merck Sharp & Dohme Corp. OXO bridged diazepan orexin receptor antagonists
EP2215075B1 (en) 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp inhibitors
WO2009081246A2 (en) * 2007-12-19 2009-07-02 Pfizer Inc. Bicyclic diamines as nicotinic receptor agonists
AU2009228945B2 (en) 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
HRP20150139T1 (hr) 2008-03-27 2015-05-22 Janssen Pharmaceutica N.V. Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
TW201004963A (en) * 2008-07-03 2010-02-01 Targacept Inc Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands
JP2012505834A (ja) * 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド ニコチン性アセチルコリン受容体リガンドおよびその使用
KR101925971B1 (ko) * 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
WO2013016160A1 (en) * 2011-07-26 2013-01-31 Merck Sharp & Dohme Corp. NOVEL IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS mTOR INHIBITORS
WO2013050938A1 (en) * 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
WO2013116413A1 (en) * 2012-02-02 2013-08-08 Targacept, Inc. Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
US10231970B2 (en) 2014-09-30 2019-03-19 NV Heterocycles Methods of producing heteropolycycles via bis-epoxidation
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
AR117169A1 (es) 2018-11-28 2021-07-14 Bayer Ag (tio)amidas de piridazina como compuestos fungicidas
BR112021010152A2 (pt) 2018-12-20 2021-11-09 Bayer Ag Heterociclil piridazina como compostos fungicidas
US20230165252A1 (en) 2020-05-27 2023-06-01 Bayer Aktiengesellschaft Active compound combinations
MX2022015970A (es) 2020-06-18 2023-01-24 Bayer Ag Combinaciones de compuestos activos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
HUP0002713A3 (en) * 1997-05-30 2001-02-28 Neurosearch As 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use
CN1205210C (zh) * 1997-05-30 2005-06-08 神经研究公司 作为尼古丁ACh受体上胆碱能配体的9-氮杂双环(3.3.1)壬-2-烯衍生物
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HK1043116A1 (en) 2002-09-06
CA2361525C (en) 2009-12-08
CZ20012716A3 (cs) 2001-11-14
HUP0200332A2 (en) 2002-06-29
PT1147112E (pt) 2004-03-31
AU773795B2 (en) 2004-06-03
CO5150231A1 (es) 2002-04-29
CA2361525A1 (en) 2000-08-03
IL144340A0 (en) 2002-05-23
ES2209825T3 (es) 2004-07-01
HK1043116B (en) 2004-10-15
DE60006213D1 (de) 2003-12-04
TR200102162T2 (tr) 2001-12-21
EP1359152B1 (en) 2008-05-07
TW200300021A (en) 2003-05-01
HUP0200332A3 (en) 2002-09-30
CN1345320A (zh) 2002-04-17
ATE394401T1 (de) 2008-05-15
EP1359152A2 (en) 2003-11-05
AR034538A1 (es) 2004-03-03
NZ512884A (en) 2004-03-26
DE60006213T2 (de) 2004-07-29
ATE253067T1 (de) 2003-11-15
SK10692001A3 (sk) 2002-01-07
DE60038823D1 (de) 2008-06-19
NO20013731D0 (no) 2001-07-30
EP1147112A1 (en) 2001-10-24
JP2002535409A (ja) 2002-10-22
EP1147112B1 (en) 2003-10-29
ES2305373T3 (es) 2008-11-01
CN1636996A (zh) 2005-07-13
AU2856900A (en) 2000-08-18
BG105836A (en) 2002-03-29
DK1147112T3 (da) 2004-02-23
JP4676062B2 (ja) 2011-04-27
KR20010101725A (ko) 2001-11-14
BR0007664A (pt) 2002-05-07
EP1359152A3 (en) 2003-12-17
WO2000044755A1 (en) 2000-08-03
ZA200105835B (en) 2002-10-16

Similar Documents

Publication Publication Date Title
NO20013731L (no) Diazabicykliske derivater som nikotinacetylkolinreseptorligander
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
MY126736A (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
MX2007003330A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
NZ514477A (en) Adamantane derivatives
MY107756A (en) Piperazine derivatives.
GB2369360A (en) 5-cyano-2-aminopyrimidine derivatives
CA2339630A1 (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
NO996108L (no) 9-oksinerytromycinderivater
IL190780A0 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
CA2295088A1 (en) Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivates
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
NO20044606L (no) Polymorfe former av lansoprazol og fremgangsmater for fremstilling derav
AU5705700A (en) Crystals of benzimidazole compounds
CA2361614A1 (en) Compositions for treating inflammatory response
PT1181299E (pt) Derivados de eritromicina modificados em c-2
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
TR200001141T2 (tr) Motilin reseptörü antagonistleri olarak yararlı siklopenten türevleri.
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
IL136911A0 (en) Heterocyclic topoisomerase poisons
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
BG103735A (en) Method for the preparation of substituted thiazolidindions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application